Indications for XERAVA:
Susceptible complicated intra-abdominal infections (cIAI) in patients ≥18yrs of age.
Limitations of Use:
Not for the treatment of complicated urinary tract infections (cUTI).
Calculate dose based on actual body weight. Give by IV infusion over 60mins. ≥18yrs: 1mg/kg every 12hrs for 4–14 days. Severe hepatic impairment (Child Pugh C): 1mg/kg every 12hrs on Day 1, then 1mg/kg every 24hrs starting on Day 2 for a total duration of 4–14 days. Concomitant strong CYP3A inducers: 1.5mg/kg every 12hrs for a total duration of 4–14 days.
<8yrs: not recommended.
Discontinue if allergic reaction or superinfection occurs. Evaluate if diarrhea occurs; discontinue if C. difficile-associated diarrhea is suspected or confirmed. Pregnancy (during 2nd & 3rd trimester): may cause permanent discoloration of the teeth or reversible inhibition of bone growth. Nursing mothers: not recommended (during and for 4 days after the last dose).
May be antagonized by strong CYP3A inducers; increase dose (see Adults). May need to reduce concomitant anticoagulant dose.
Infusion site reactions, nausea, vomiting, diarrhea, hypotension, wound dehiscence; hypersensitivity reactions, tooth discoloration, enamel hypoplasia, inhibition of bone growth (up to 8yrs of age), C.difficile-associated diarrhea, photosensitivity, pseudotumor cerebri, increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, abnormal LFTs.
Generic Drug Availability:
Single-dose vials—1, 12